Subacute myelo-optic neuropathy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jyostna Chouturi, M.B.B.S [2]
Overview
Subacute myelo-optic neuropathy (SMON) is an iatrogenic disease of the nervous system[1] leading to a disabling paralysis, blindness and even death.
Epidemiology and Demographics
Its defining manifestation was as an epidemic in Japan during the 1960s, affecting an estimated 30,000 people.[2] On August 3, 1978, the Tokyo District Court ruled that the cause of SMON is Clioquinol. Its manufacturer, Ciba-Geigy, has publicly stated that "Medical products manufactured and sold by us have been responsible for the occurrence of [SMON] in Japan, we extend our apologies."[2]. SMON was first observed and diagnosed in Sweden 1966, by the pediatrician and neurologist Olle Hansson.[3] Clioquinol was marketed as a prophylaxis to tourist diarrhoea. Dr. Olle Hansson was in the front line, fighting for a ban of clioquinol. Doctors in many countries boycotted Ciba-Geigy for many years. Not until 1985 was the pharmaceutical withdrawn. Dr Hansson died a few months later. The day of his death, May 23, is observed as the Anti-Hazardous Drug Day in several parts of the world.
References
Further reading
- Reisaku Kono, "Relation between Subacute Myelo-Optic Neuropathy (S.M.O.N.) and Clioquinol: Nationwide Survey", The Lancet, V301, I7796, January 27, 1973, pp. 171–173
- Reisaku Kono, "The S.M.O.N. Virus Theory", The Lancet, V306, I7930, August 23, 1975, pp. 370–371
- Reisaku Kono, Yoshigoro Kuroiwa, "Subacute Myelo-Optic Neuropathy is not a special form of multiple sclerosis", The Lancet, V320, I8292, July 31, 1982, p. 267
- Hansson, Olle: "Inside Ciba-Geigy". IOCU 1989. ISBN 967-9973-26-3.
Lua error in Module:Authority_control at line 788: attempt to index field 'wikibase' (a nil value).